LeMaitre Vascular (LMAT) to Release Quarterly Earnings on Thursday

LeMaitre Vascular (NASDAQ:LMAT) is set to issue its quarterly earnings data after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of $0.44 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. During the same period last year, the business earned $0.37 earnings per share. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. On average, analysts expect LeMaitre Vascular to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

LeMaitre Vascular Stock Performance

Shares of LMAT stock opened at $86.97 on Thursday. The firm has a market cap of $1.95 billion, a P/E ratio of 57.60, a P/E/G ratio of 2.45 and a beta of 0.88. The firm’s 50 day moving average price is $89.22 and its 200-day moving average price is $81.97. LeMaitre Vascular has a one year low of $44.27 and a one year high of $93.32.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend was Thursday, August 15th. LeMaitre Vascular’s payout ratio is 42.38%.

Analyst Upgrades and Downgrades

LMAT has been the subject of a number of research reports. Barrington Research reaffirmed an “outperform” rating and issued a $92.00 price objective on shares of LeMaitre Vascular in a research note on Friday, September 20th. Lake Street Capital started coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They set a “buy” rating and a $105.00 price target on the stock. JMP Securities raised their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Finally, Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price on the stock. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $94.67.

Insider Transactions at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.